Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
William Tam
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Living Beings
Chemicals & Drugs
Anatomy
Concepts & Ideas
Disorders
Sign-in to see full Profile
Network (preview)
12
Worcel, Manuel
10
Sabolinski, Michael
9
Cohn, Jay
8
Taylor, Anne
5
Letts, Gordon
5
Garvey, David
5
Janero, David
4
Ghali, Jalal
4
Marek, Przemyslaw
4
Shumway, Matthew
4
Young, Delano
4
Zaczek, Robert
3
Schroeder, Joseph
3
Lindenfeld, JoAnn
3
Ofili, Elizabeth
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of William Tam (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: McNamara Dennis M; Tam S William; Sabolinski Michael L; Tobelmann Page; Janosko Karen; Venkitachalam Lakshmi; Ofili Elizabeth; Yancy Clyde; Feldman Arthur M; Ghali Jalal K; Taylor Anne L; Cohn Jay N; Worcel Manuel
Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A-HeFT trial.
Journal of cardiac failure 2009;15(3):191-8.
-
2008: Ghali Jalal K; Tam S William; Sabolinski Michael L; Taylor Anne L; Lindenfeld Joann; Cohn Jay N; Worcel Manuel
Exploring the potential synergistic action of spironolactone on nitric oxide-enhancing therapy: insights from the African-American Heart Failure Trial.
Journal of cardiac failure 2008;14(9):718-23.
-
2007: Cohn Jay N; Tam S William; Anand Inder S; Taylor Anne L; Sabolinski Michael L; Worcel Manuel;
Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT.
Journal of cardiac failure 2007;13(5):331-9.
-
2007: Taylor Anne L; Ziesche Susan; Yancy Clyde W; Carson Peter; Ferdinand Keith; Taylor Malcolm; Adams Kirkwood; Olukotun Adeoye Y; Ofili Elizabeth; Tam S William; Sabolinski Michael L; Worcel Manuel; Cohn Jay N;
Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial.
Circulation 2007;115(13):1747-53.
-
2007: Anand Inder S; Tam S William; Rector Thomas S; Taylor Anne L; Sabolinski Michael L; Archambault W Tad; Adams Kirkwood F; Olukotun Adeoye Y; Worcel Manuel; Cohn Jay N
Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial.
Journal of the American College of Cardiology 2007;49(1):32-9.
-
2007: Ghali Jalal K; Tam S William; Ferdinand Keith C; Lindenfeld JoAnn; Sabolinski Michael L; Taylor Anne L; Worcel Manuel; Curry Charles L; Cohn Jay N;
Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial.
American journal of cardiovascular drugs : drugs, devices, and other interventions 2007;7(5):373-80.
-
2007: Tam S William; Sabolinski Michael L; Worcel Manuel; Packer Milton; Cohn Jay N
Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox.
Clinical pharmacokinetics 2007;46(10):885-95.
-
2006: Taylor Anne L; Lindenfeld JoAnn; Ziesche Susan; Walsh Mary Norine; Mitchell Judith E; Adams Kirkwood; Tam S William; Ofili Elizabeth; Sabolinski Michael L; Worcel Manuel; Cohn Jay N;
Outcomes by gender in the African-American Heart Failure Trial.
Journal of the American College of Cardiology 2006;48(11):2263-7.
-
2006: McNamara Dennis M; Tam S William; Sabolinski Michael L; Tobelmann Page; Janosko Karen; Taylor Anne L; Cohn Jay N; Feldman Arthur M; Worcel Manuel
Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A-HeFT Trial.
Journal of the American College of Cardiology 2006;48(6):1277-82.
-
2005: Angus Derek C; Linde-Zwirble Walter T; Tam S William; Ghali Jalal K; Sabolinski Michael L; Villagra Victor G; Winkelmayer Wolfgang C; Worcel Manuel;
Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure.
Circulation 2005;112(24):3745-53.
-
2005: Kernohan A F B; McIntyre M; Hughes D M; Tam S W; Worcel M; Reid J L
An oral yohimbine/L-arginine combination (NMI 861) for the treatment of male erectile dysfunction: a pharmacokinetic, pharmacodynamic and interaction study with intravenous nitroglycerine in healthy male subjects.
British journal of clinical pharmacology 2005;59(1):85-93.
-
2004: Lin Chia-En; Garvey David S; Janero David R; Letts L Gordon; Marek Przemyslaw; Richardson Stewart K; Serebryanik Diana; Shumway Matthew J; Tam S William; Trocha A Mark; Young Delano V
Combination of paclitaxel and nitric oxide as a novel treatment for the reduction of restenosis.
Journal of medicinal chemistry 2004;47(9):2276-82.
-
2004: Ranatunge Ramani R; Augustyniak Michael; Bandarage Upul K; Earl Richard A; Ellis James L; Garvey David S; Janero David R; Letts L Gordon; Martino Allison M; Murty Madhavi G; Richardson Stewart K; Schroeder Joseph D; Shumway Matthew J; Tam S William; Trocha A Mark; Young Delano V
Synthesis and selective cyclooxygenase-2 inhibitory activity of a series of novel, nitric oxide donor-containing pyrazoles.
Journal of medicinal chemistry 2004;47(9):2180-93.
-
2003: Khanapure Subhash P; Garvey David S; Young Delano V; Ezawa Maiko; Earl Richard A; Gaston Rick D; Fang Xinqin; Murty Madhavi; Martino Allison; Shumway Matthew; Trocha Mark; Marek Przemyslaw; Tam S William; Janero David R; Letts L Gordon
Synthesis and structure-activity relationship of novel, highly potent metharyl and methcycloalkyl cyclooxygenase-2 (COX-2) selective inhibitors.
Journal of medicinal chemistry 2003;46(25):5484-504.
-
2001: Tam S W; Worcel M; Wyllie M
Yohimbine: a clinical review.
Pharmacology & therapeutics 2001;91(3):215-43.
-
2000: Bandarage U K; Chen L; Fang X; Garvey D S; Glavin A; Janero D R; Letts L G; Mercer G J; Saha J K; Schroeder J D; Shumway M J; Tam S W
Nitrosothiol esters of diclofenac: synthesis and pharmacological characterization as gastrointestinal-sparing prodrugs.
Journal of medicinal chemistry 2000;43(21):4005-16.
-
2000: Young D V; Serebryanik D; Janero D R; Tam S W
Suppression of proliferation of human coronary artery smooth muscle cells by the nitric oxide donor, S-nitrosoglutathione, is cGMP-independent.
Molecular cell biology research communications : MCBRC 2000;4(1):32-6.
-
1999: Gilligan P J; He L; Culp S; Fitzgerald L; Tam S W; Wong Y N
Structure-activity studies on 4-substituted-2-anilinopyrimidine corticotropin releasing factor (CRF) antagonists.
Bioorganic & medicinal chemistry 1999;7(11):2321-8.
-
1999: de Tejada I S; Garvey D S; Schroeder J D; Shelekhin T; Letts L G; Fernández A; Cuevas B; Gabancho S; Martínez V; Angulo J; Trocha M; Marek P; Cuevas P; Tam S W
Design and evaluation of nitrosylated alpha-adrenergic receptor antagonists as potential agents for the treatment of impotence.
The Journal of pharmacology and experimental therapeutics 1999;290(1):121-8.
-
1999: Arvanitis A G; Gilligan P J; Chorvat R J; Cheeseman R S; Christos T E; Bakthavatchalam R; Beck J P; Cocuzza A J; Hobbs F W; Wilde R G; Arnold C; Chidester D; Curry M; He L; Hollis A; Klaczkiewicz J; Krenitsky P J; Rescinito J P; Scholfield E; Culp S; De Souza E B; Fitzgerald L; Grigoriadis D; Tam S W; Shen H L
Non-peptide corticotropin-releasing hormone antagonists: syntheses and structure-activity relationships of 2-anilinopyrimidines and -triazines.
Journal of medicinal chemistry 1999;42(5):805-18.
-
1998: Earl R A; Zaczek R; Teleha C A; Fisher B N; Maciag C M; Marynowski M E; Logue A R; Tam S W; Tinker W J; Huang S M; Chorvat R J
2-Fluoro-4-pyridinylmethyl analogues of linopirdine as orally active acetylcholine release-enhancing agents with good efficacy and duration of action.
Journal of medicinal chemistry 1998;41(23):4615-22.
-
1997: Weaver C E; Marek P; Park-Chung M; Tam S W; Farb D H
Neuroprotective activity of a new class of steroidal inhibitors of the N-methyl-D-aspartate receptor.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(19):10450-4.
-
1995: Tam S W; Zaczek R
Linopirdine. A depolarization-activated releaser of transmitters for treatment of dementia.
Advances in experimental medicine and biology 1995;363():47-56.
-
1994: Maciag C M; Logue A R; Tinker W J; Saydoff J A; Tam S W; Zaczek R
Studies on the role of K+, Cl- and Na+ ion permeabilities in the acetylcholine release enhancing effects of linopirdine (DuP 996) in rat cortical slices.
The Journal of pharmacology and experimental therapeutics 1994;271(2):891-7.
-
1994: Cheng C Y; Hsin L W; Tsai M C; Schmidt W K; Smith C; Tam S W
Synthesis and opioid activity of 7-oxygenated 2,3,4,4a,5,6,7,7a-octahydro-1H-benzofuro[3,2-e]isoquinolin-9-ols.
Journal of medicinal chemistry 1994;37(19):3121-7.
-
1993: Wong P C; Duncia J V; Chiu A T; Olson R E; Rominger D H; Tam S W; Timmermans P B
EXP063, a nonpeptide angiotensin II and beta adrenergic receptor antagonist.
The Journal of pharmacology and experimental therapeutics 1993;267(2):641-7.
-
1993: Wilkerson W W; Kergaye A A; Tam S W
3-Substituted, 3-(4-pyridinylmethyl)-1,3-dihydro-1-phenyl-2H-indol-2-ones as acetylcholine release enhancers: synthesis and SAR.
Journal of medicinal chemistry 1993;36(20):2899-907.
-
1993: Watanabe M; Rominger D; Hurt S D; De Souza E B; Tam S W
[3H]1-(cyclopropylmethyl)-4-(2-(4-fluorophenyl)-2-oxoethyl) piperidine HBr (DuP 734). A selective ligand for sigma receptors in mouse brain in vivo.
The Journal of pharmacology and experimental therapeutics 1993;266(3):1541-8.
-
1993: Dent G W; Rule B L; Tam S W; De Souza E B
Effects of the memory enhancer linopirdine (Dup 996) on cerebral glucose metabolism in naive and hypoxia-exposed rats.
Brain research 1993;620(1):7-15.
-
1993: Zaczek R; Tinker W J; Tam S W
Unique properties of norepinephrine release from terminals arising from the locus coeruleus: high potassium sensitivity and lack of linopirdine (DuP 996) enhancement.
Neuroscience letters 1993;155(1):107-11.
-
1992: Heroux J A; Tam S W; De Souza E B
Autoradiographic identification and characterization of sigma receptors in guinea pig brain using [3H]1(cyclopropylmethyl)-4-(2'-(4''-fluorophenyl)-2'-oxoethyl) piperidine ([3H]DuP 734), a novel sigma receptor ligand.
Brain research 1992;598(1-2):76-86.
-
1992: Culp S G; Rominger D; Tam S W; De Souza E B
[3H]DuP 734 [1-(cyclopropylmethyl)-4-(2'-(4''-fluorophenyl)-2'- oxoethyl)-piperidine HBr]: a receptor binding profile of a high-affinity novel sigma receptor ligand in guinea pig brain.
The Journal of pharmacology and experimental therapeutics 1992;263(3):1175-87.
-
1992: Tam S W; Steinfels G F; Gilligan P J; Schmidt W K; Cook L
DuP 734 [1-(cyclopropylmethyl)-4-(2'(4''-fluorophenyl)-2'-oxoethyl)- piperidine HBr], a sigma and 5-hydroxytryptamine2 receptor antagonist: receptor-binding, electrophysiological and neuropharmacological profiles.
The Journal of pharmacology and experimental therapeutics 1992;263(3):1167-74.
-
1992: Cook L; Tam S W; Rohrbach K W
DuP 734 [1-(cyclopropylmethyl)-4-(2'(4''-fluorophenyl)-2'- oxoethyl)piperidine HBr], a potential antipsychotic agent: preclinical behavioral effects.
The Journal of pharmacology and experimental therapeutics 1992;263(3):1159-66.
-
1992: De Souza E B; Rule B L; Tam S W
[3H]linopirdine (DuP 996) labels a novel binding site in rat brain involved in the enhancement of stimulus-induced neurotransmitter release: autoradiographic localization studies.
Brain research 1992;582(2):335-41.
-
1992: Cheng C Y; Wu S C; Hsin L W; Tam S W
Selective reversible and irreversible ligands for the kappa opioid receptor.
Journal of medicinal chemistry 1992;35(12):2243-7.
-
1991: Tam S W; Rominger D; Nickolson V J
Novel receptor site involved in enhancement of stimulus-induced acetylcholine, dopamine, and serotonin release.
Molecular pharmacology 1991;40(1):16-21.
-
1991: Wong P C; Tam S W; Herblin W F; Timmermans P B
Further studies on the selectivity of DuP 753, a nonpeptide angiotensin II receptor antagonist.
European journal of pharmacology 1991;196(2):201-3.
-
1990: Cheng C Y; Lu H Y; Lee F M; Tam S W
Synthesis of (1',2'-trans)-3-phenyl-1-[2'-(N-pyrrolidinyl)cyclohexyl]pyrrolid -2-ones as kappa-selective opiates.
Journal of pharmaceutical sciences 1990;79(8):758-62.
-
1989: Steinfels G F; Tam S W; Cook L
Electrophysiological effects of selective sigma-receptor agonists, antagonists, and the selective phencyclidine receptor agonist MK-801 on midbrain dopamine neurons.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1989;2(3):201-8.
-
1989: Steinfels G F; Tam S W
Selective sigma receptor agonist and antagonist affect dopamine neuronal activity.
European journal of pharmacology 1989;163(1):167-70.
-
1988: Steinfels G F; Alberici G P; Tam S W; Cook L
Biochemical, behavioral, and electrophysiologic actions of the selective sigma receptor ligand (+)-pentazocine.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1988;1(4):321-7.
-
1987: Steinfels G F; Tam S W; Cook L
Discriminative stimulus properties of a sigma receptor agonist in the rat: role of monoamine systems.
European journal of pharmacology 1987;141(1):163-6.
-
1987: Herblin W F; Kauer J C; Tam S W
Photoinactivation of the mu opioid receptor using a novel synthetic morphiceptin analog.
European journal of pharmacology 1987;139(3):273-9.
-
1987: Steinfels G F; Tam S W; Cook L
Discriminative stimulus properties of (+)-N-allylnormetazocine in the rat: correlations with (+)-N-allylnormetazocine and phencyclidine receptor binding.
Psychopharmacology 1987;91(1):5-9.
-
1986: Steinfels G F; Tam S W; Cook L
(+)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine [(+)-3-PPP] but not (-)-3-PPP produces (+)-N-allylnormetazocine-like (SKF 10,047) discriminative stimuli.
Life sciences 1986;39(26):2611-5.
-
1986: Tam S W; Liu-Chen L Y
Reversible and irreversible binding of beta-funaltrexamine to mu, delta and kappa opioid receptors in guinea pig brain membranes.
The Journal of pharmacology and experimental therapeutics 1986;239(2):351-7.
-
1985: Tam S W; Nickolson V J; Liu-Chen L Y
[3H]beta-funaltrexamine binds covalently to brain opioid receptors.
European journal of pharmacology 1985;119(3):259-60.
-
1985: Schmidt W K; Tam S W; Shotzberger G S; Smith D H; Clark R; Vernier V G
Nalbuphine.
Drug and alcohol dependence 1985;14(3-4):339-62.
Sign-in to see more
